Skip to main content
SpringerLink
Log in

Hereditary Cancers

  • Chapter
  • First Online:
Management of Endometrial Cancer

Abstract

Every year, epithelial endometrial cancer (EC) incidence accounts for 7% of all cancers in women worldwide, representing the fourth most common malignancy arising in women. In the United States alone, over 54,000 new cases are expected and over 10,170 women will die of this disease in 2015 [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, et al. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  2. Weir HK. The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer. 2015;121:1827.

    Article  PubMed  Google Scholar 

  3. Gruber SB, Thompson WD. A population-based study of endometrial cancer and familial risk in younger women. cancer and steroid hormone study group. Cancer Epidemiol Biomark Prev. 1996;5(6):411–7.

    CAS  Google Scholar 

  4. Watson P, Lynch H. Extracolonic cancer in hereditary non poliposis colon rectal cancer. Cancer. 1993;71:677.

    Article  CAS  PubMed  Google Scholar 

  5. Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 1985;45:1437–43.

    CAS  PubMed  Google Scholar 

  6. Dunlop MG, Farrington SM, Nicholl I, et al. Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer. 2000;83(12):1643–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hendriks YM, De Jong AE, Morreau H, et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin. 2006;56:213–25.

    Article  PubMed  Google Scholar 

  8. Jass JR. Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World J Gastroenterol. 2006;12:4943–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6(1):105–10.

    Article  CAS  PubMed  Google Scholar 

  10. Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet. 2008;74(3):233–42.

    Article  CAS  PubMed  Google Scholar 

  11. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137(5):1621–7.

    Article  PubMed  Google Scholar 

  12. Barrow E, Hill J, Evans DG. Cancer risk in Lynch syndrome. Familial Cancer. 2013;12(2):229–40.

    Article  CAS  PubMed  Google Scholar 

  13. Palomaki GE, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11(1):42–65.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet. 2009;41:112–7.

    Article  CAS  PubMed  Google Scholar 

  15. Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell. 2013;155(4):858–68.

    Article  CAS  PubMed  Google Scholar 

  16. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2 and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304.

    Article  CAS  PubMed  Google Scholar 

  17. Senter L, Clendenning M, Sotamaa K, et al. Th e clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135:419–28.

    Article  CAS  PubMed  Google Scholar 

  18. Ligtenberg MJ, Kuiper RP, Geurts van Kessel A, Hoogerbrugge N. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Familial Cancer. 2013;12(2):169.

    Article  CAS  PubMed  Google Scholar 

  19. Aarnio M, et al. Clinicopathological features and management of cancers in lynch syndrome. Pathol Res Int. 2012:350309.

    Google Scholar 

  20. Lu KE, Schorge JO, et al. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007;25(33):5158–64.

    Article  CAS  PubMed  Google Scholar 

  21. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic malignancy as a “sentinel cancer” for women with HNPCC. Obstet Gynecol. 2005;105:569–74.

    Article  PubMed  Google Scholar 

  22. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006;106:87.

    Article  CAS  PubMed  Google Scholar 

  23. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol. 2008;26:5965.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Boks DE, Trujillo AP, Voogd AC, et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer. 2002;102(2):198–200.

    Article  CAS  PubMed  Google Scholar 

  25. Vasen HFA, Mecklin JP, Meera Khan P, et al. The international collaborative group on hereditary non-polyposis colorectal cancer. Dis Colon Rectum. 1991;34:424–5.

    Article  CAS  PubMed  Google Scholar 

  26. Vasen HFA, Watson P, Mecklin JP, et al. New criteria for hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC (ICG-HNPCC). Gastroenterology. 1999;116:1453–6.

    Article  CAS  PubMed  Google Scholar 

  27. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.

    Article  CAS  PubMed  Google Scholar 

  28. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293:1979–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. American Gastroenterological Association. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121(1):195.

    Article  Google Scholar 

  30. Umar A, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.

    Article  CAS  PubMed  Google Scholar 

  31. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 2014;109(8):1159–79.

    Article  PubMed  Google Scholar 

  32. Lancaster JM, et al. SGO Committee statement Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107:159–62.

    Article  PubMed  Google Scholar 

  33. Green RC, Parfrey PS, Woods MO, et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst. 2009;101:331–40.

    Article  PubMed  Google Scholar 

  34. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repairs genes in colon cancer. N Engl J Med. 2006;354:2751–63.

    Article  CAS  PubMed  Google Scholar 

  35. Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology. 2011;40:73–81.

    Article  Google Scholar 

  36. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res. 2010;4:9–22.

    Article  Google Scholar 

  37. Mercado RC, Hampel H, Kastrinos F, et al. Performance of PREMM1,2, 6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med. 2012;14(7):670–80.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Backes FJ, Leon ME, Ivanov I, et al. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecol Oncol. 2009;114:486–90.

    Article  CAS  PubMed  Google Scholar 

  39. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.

    Article  CAS  PubMed  Google Scholar 

  40. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11:42–65.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28:E32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP, Errami A. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33:e128.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Newton K, Jorgensen NM, Wallace AJ, et al. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch syndrome (HNPCC) et al. J Med Genet. 2014;51:789–96.

    Article  CAS  PubMed  Google Scholar 

  44. American College of Obstetricians and Gynecologists. Lynch syndrome. Practice Bulletin No. 147. Obstet Gynecol. 2014;124:1042–54.

    Article  Google Scholar 

  45. Society of Gynecologic Oncology. SGO clinical practice statement: screening for Lynch syndrome in endometrial cancer. Chicago: SGO; 2014. https://www.sgo.org/clinical-practice/guidelines/screeningfor-lynch-syndrome-in-endometrial-cancer/. Retrieved 22 July 2014.

  46. Resnick KE, Hampel H, Fishel R, et al. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Gynecol Oncol. 2009;114(1):128–34.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Society of Gynecologic Oncology. SGO clinical practice statement: screening for Lynch syndrome in endometrial cancer. Chicago: SGO; 2014. https://www.sgo.org/clinical-practice/guidelines/screeningfor-lynch-syndrome-in-endometrial-cancer/. Retrieved May 2015.

  48. Jarvinen HJ, Aarnio M, Mustonen M, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829.

    Article  CAS  PubMed  Google Scholar 

  49. Lindor NM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293:1979–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer. 2002;94:1708.

    Article  PubMed  Google Scholar 

  51. Renkonen-Sinisalo L, Bützow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer. 2007;120(4):821.

    Article  CAS  PubMed  Google Scholar 

  52. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354(3):261–9.

    Article  CAS  PubMed  Google Scholar 

  53. Chung L, Broaddus R, Crozier M, Luthraa R, Levenback C, Lu K. Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol. 2003;102(5 Pt 2):1152–5.

    PubMed  Google Scholar 

  54. Kwon JS, Sun CC, Peterson SK, et al. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer. 2008;113:326–35.

    Article  PubMed  Google Scholar 

  55. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med. 1980;302:551–4.

    Article  CAS  PubMed  Google Scholar 

  56. Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125:263–70.

    Article  CAS  PubMed  Google Scholar 

  57. Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, et al. Prospective, multi-center randomized intermediate biomarker study of oral contraceptive vs. Depo-Provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res. 2013;6:774–81.

    Article  Google Scholar 

  58. Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359:2567–78.

    Article  CAS  PubMed  Google Scholar 

  59. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized controlled trial. Lancet. 2011;378:2081–7.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet. 2011;377:31–41.

    Article  CAS  PubMed  Google Scholar 

  61. National Comprehensive Cancer Network. Clinical practice guidelines in oncology genetic/familial high risk assessment: colorectal (Version 3.2019). https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Accessed June 2019.

  62. Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol. 2005;6:980.

    Article  PubMed  Google Scholar 

  63. South CD, et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008;100(4):277.

    Article  CAS  PubMed  Google Scholar 

  64. Gustafson S, Zbuk KM, Scacheri C, et al. Cowden syndrome. Semin Oncol. 2007;34(5):428–34.

    Article  CAS  PubMed  Google Scholar 

  65. Tan M-H, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime Cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7. https://doi.org/10.1158/1078-0432.CCR-11-2283.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. National Comprehensive Cancer Network. Clinical practice guidelines in oncology genetic/familial high risk assessment: breast and ovarian (Version 2.2014). https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 22 June 2019.

  67. Levine D, Lin O, Barakat R, et al. Risk of endometrial cancer associated with BRCA mutation. Gynecol Oncol. 2001;80(3):395–8.

    Article  CAS  PubMed  Google Scholar 

  68. Biener M, Fich A, Rosen B, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007;104:7.

    Article  Google Scholar 

  69. Segev Y1, Iqbal J, Lubinski J, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013;130(1):127–31.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Cancer Research, The Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Lorenzo Ceppi, Don S. Dizon & Michael J. Birrer

  2. Department of Medicine and Surgery, Milano-Bicocca University, ASST-Monza, Desio Hospital, Monza, Italy

    Lorenzo Ceppi

  3. O’Neal Cancer Center, Birmingham, AL, USA

    Michael J. Birrer

Authors
  1. Lorenzo Ceppi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Don S. Dizon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael J. Birrer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Birrer .

Editor information

Editors and Affiliations

  1. Rigshospitalet, Copenhagen University Rigshospitalet, København Ø, Denmark

    Mansoor R. Mirza

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ceppi, L., Dizon, D.S., Birrer, M.J. (2020). Hereditary Cancers. In: Mirza, M. (eds) Management of Endometrial Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-64513-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64513-1_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64512-4

  • Online ISBN: 978-3-319-64513-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation